What is William Blair’s Estimate for Genmab A/S Q1 Earnings?

Genmab A/S (NASDAQ:GMAB) – Stock analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of Genmab A/S in a research report issued on Tuesday, March 18th. William Blair analyst M. Phipps forecasts that the company will post earnings per share of $0.37 for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share. William Blair also issued estimates for Genmab A/S’s Q2 2026 earnings at $0.57 EPS, Q3 2026 earnings at $0.62 EPS and Q4 2026 earnings at $0.67 EPS.

GMAB has been the subject of a number of other reports. Truist Financial cut their price objective on Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Tuesday, March 11th. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research report on Thursday, January 23rd. BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Finally, Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Four research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Genmab A/S has an average rating of “Moderate Buy” and an average price target of $41.33.

Genmab A/S Trading Up 0.2 %

Shares of NASDAQ:GMAB opened at $20.25 on Wednesday. The business has a 50-day moving average price of $21.14 and a 200 day moving average price of $22.26. The company has a market capitalization of $13.40 billion, a price-to-earnings ratio of 11.64, a PEG ratio of 2.65 and a beta of 0.98. Genmab A/S has a 12-month low of $18.64 and a 12-month high of $31.02.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds and other institutional investors have recently made changes to their positions in GMAB. Deep Track Capital LP purchased a new position in shares of Genmab A/S in the 4th quarter valued at about $41,740,000. Brandywine Global Investment Management LLC purchased a new position in shares of Genmab A/S in the 4th quarter valued at about $33,804,000. Two Sigma Advisers LP boosted its stake in shares of Genmab A/S by 168.8% in the 4th quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company’s stock valued at $34,509,000 after buying an additional 1,038,400 shares during the period. Two Sigma Investments LP boosted its stake in shares of Genmab A/S by 122.2% in the 4th quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company’s stock valued at $35,612,000 after buying an additional 938,455 shares during the period. Finally, Marshall Wace LLP boosted its stake in shares of Genmab A/S by 162.2% in the 4th quarter. Marshall Wace LLP now owns 1,122,296 shares of the company’s stock valued at $23,422,000 after buying an additional 694,243 shares during the period. Hedge funds and other institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.